Treatment duration proves critical variable where longer courses create more durable changes - users completing 2-3 month treatments typically maintain 20-40% of peak benefits long-term, 4-6 month treatments sustain 40-60% of improvements, and 6-12+ month courses preserve 50-70% of maximum benefits potentially indefinitely
Experimental models have demonstrated that interference with TF expression or activity reduces tumor outgrowth and metastatic potential, while clinically, overexpression of TF has been found to be associated with disease progression and poor prognosis in solid tumors 146,147
Light stomach discomfort or nausea
Despite its potential, BPC 157s lack of extensive human studies and FDA approval highlights the need for further research to establish its safety and efficacy
Researchers might monitor cell morphology, gene expression changes, or biochemical markers such as oxidative stress indicators and extracellular matrix components